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Abstract: Pharmacists in Poland are responsible for the dispensing and quality control of
pharmaceuticals. The education process in pharmacy is regulated and monitored at the national
level. Pharmacy education at Jagiellonian University is organized in a traditional way based on input
and content teaching. The aim of the study was to determinate whether the Jagiellonian University
curriculum in the Pharmacy program meets the criteria of the European Competence Framework.
The mapping of the intended curriculum was done by four academic teachers. The qualitative and
quantitative analysis of the distribution of the European Competence Framework among a group of
courses and study years was done. We observed that most of the personal competencies are offered
to students in their senior years, while the patient care competencies are distributed equally during
the cycle of the study, and only some of them are overrepresented at the senior years. We need a
legislation change at the national level as well as organizational and mental change at the university
level to move from learning outcome-based pharmacy education to competence-based.
Keywords: learning outcomes; pharmacy; competence framework; higher education institution
1. Introduction
The Pharmacist designation in Poland is recognized in the Polish Health System as a profession
responsible for the dispensing and quality control of pharmaceuticals [1]. According to the Constitution
of the Republic of Poland, the pharmacist is considered as a “profession in which the public repose
confidence, ( . . . ) and self-governments shall concern themselves with the proper practice of such
professions in accordance with, and for the purpose of protecting, the public interest” [2]. It also
constitutes pharmacists as a “regulated profession”, which is in accordance with the European
Directive [3].
The pharmacist profession in Poland is still seen as a stable and well-paid. Analysis of the labor
market showed that pharmacy graduates need only about 2–4 weeks to be employed, and during the
first two years after graduation, their salaries are higher than any other medical graduates [4]. Due to
the European Directive, the Master Diploma in Pharmacy (MDPharm) awarded in Poland is recognized
in EU states, which improves the mobility among pharmacists and determines the competitiveness of
the profession compared to other graduates [4,5]. Therefore, the main determinant which influenced
the decision of young adults in choosing the pharmacy school in Poland is the confidence that in the
future they will be able to find a well-paid position in Poland or in EU states [6].
Pharmaceutical education in Poland is based on the Bologna process, which regulation was
implemented into the Higher Education System in Poland at the beginning of the XXI century [7,8].
As a regulated profession, the pharmacist is one of the health professions for which education is based
on national standards established by law act amended by the Ministry of Science and Higher Education
(MSHE) [9].
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The National Standards for Pharmacy Education Act consists of five parts: (1) general
requirements for pharmacy program, (2) general learning outcomes (gLO), (3) specific learning
outcomes (sLO), (4) organization of the process of education, and (5) methods recommended to
be used in the assessment process. The minimal requirements for the MDPharm program are the
following: 11 semesters with no less than 5300 contact hours at courses and internships and 330
ECTS (European Credit Transfer System) in total. The general and specific learning outcomes are
described as learning outcomes in knowledge, professional, and social skills. The specific learning
outcomes are grouped into five main dimensions of sciences, such as (A) biomedical and humanistic
sciences; (B) physics and chemistry; (C) analysis, synthesis, and technology; (D) biopharmacy and
pharmacotherapy outcomes; (E) pharmacy practice; and (F) student’s scientific project. In Table 1,
the distribution of contact hours and ECTS credits established in the national standard for pharmacy is
presented in detail. The learning outcomes in the Polish National Standard for Pharmacy are described
separately for knowledge and professional or social skills [9].
Table 1. The National Standard for Pharmacy—distribution of contact hours and credits in the main
scientific and internship dimensions [9].
Area Topic Group Name Contact Hours forStudent (in Total) ECTS
Basic sciences
(A) biomedical and humanistic sciences 660
98(B) physics and chemistry 765
Pharmaceutical Sciences
(C) analysis, synthesis, and technology 840
140
(D) biopharmacy and pharmacotherapy outcomes 480
(E) pharmacy practice 410
(F) scientific project 375
Internships (I) holiday internships 320 10
(IS) senior students internship (6-month) 960 40
Despite the regulation described above, the autonomy of universities empowers academics to
develop, plan, and organize the specific MDPharm program as well as to use teaching methods which
ensure that student will achieve the learning outcomes established in the national standard [9].
Nowadays, among the ten Faculties of Pharmacy located in the main medical universities in
Poland, approximately 1500 students graduate each year, who mainly start their professional work as
pharmacists in the community and in hospital pharmacies [4,5]. In the last twenty years in pharmacy
education, we observed the tendency to switch from chemistry-based pharmacy which was focused
on the medicinal product, to medicine-based pharmacy which is more patient-oriented [10].
Jagiellonian University established a quality control system which aims to analyze and improve
the education process to ensure that it fulfills the national standards. The Faculty of Pharmacy at
Jagiellonian University Medical College (FP-JUCM) with a 250-year tradition in pharmacy teaching is
one of the oldest schools of pharmacy in Central-Eastern Europe and the oldest in Poland; for the last
few years, it has also been recognized as the best one in Poland [11].
The education process in the MDPharm at FP-JUCM is organized in a traditional way based on
input and content teaching; this means that the student has to participate and pass the final exams of
obligatory and optional courses and internships. The course syllabus contains the description of the
learning outcomes and information about the teaching and evaluation methods, which are used to
ensure that the student will achieve all learning outcomes. The FP-UJCM offers pharmacy students
about one hundred separate courses, and half of them are obligatory. Despite obligatory courses,
the student is obliged to pass at least twenty-two optional courses. Each of the obligatory courses
should cover sLO described in the national standard for pharmacy. In Table 2, detailed information
about the distribution of the sLO in the obligatory courses in pharmacy is shown. According to
the Polish National Standard for Pharmacy, the MDPharm program covers 5.5 years of courses and
internships, including six months of internship in community or hospital pharmacy [9].
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Table 2. The quantitative analysis of the distribution of the specific learning outcomes (sLO) into
the courses in the Master Diploma in Pharmacy (MDPharm) program at the Faculty of Pharmacy at
Jagiellonian University Medical College (FP-JUCM) [9].
Courses in Specific Topic Group
Learning Outcomes (n *)
Knowledge Professional Skills Social Skills
(A) Biology/Genetics, Anatomy, Physiology,
Pathophysiology, Biochemistry, Immunology,
Molecular Biology, Microbiology, Botanics, First Aid,
Philosophy, Psychology
32 22 3
(B) Biophysics, Inorganic and Organic Chemistry,
Analytical Chemistry, Maths, Statistic, IT technology 27 17 3
(C) Medicinal Chemistry, Medicinal synthesis,
Biotechnology, Pharmacognosis,
Pharmaceutical Technology
41 17 -
(D) Biopharmacy, Pharmacokinetics, Pharmacology,
Toxicology, Bromatology, Herbal drugs 47 69 -
(E) Pharmaceutical care, Clinical Pharmacy, Law and
Ethics, Pharmacoeconomics, Epidemiology,
Drug Information, Pharmacy Practice
55 55 -
(F) Scientific project 2 6 -
* number of learning outcomes in specific category.
A “set of competencies for pharmacists” was presented as one of the results of “Pharmacy
Education in Europe—PHARMINE project” Afterwards, The PHAR-QA consortium together with
the European Association of Faculties of Pharmacies extended the PHARMINE results to “produce a
harmonized model for quality assurance in pharmacy education” [12]. The European Competence
Framework (ECF) is one of core results of PHAR-QA project, which could be used in “setting up
and/or modifying curricula in European pharmacy departments” [12]. ECF is a list of competencies for
pharmacists. They consist of the two major categories—personal competence and patient care competences,
which are divided into four and seven subcategories, respectively [13].
The aim of our study was to determine whether the FP-JUCM curriculum program in the
MDPharm meets the criteria of the European Competence Framework [13] and to recognize the gaps
and areas which need to be improved if we want our graduates to be a competent and well-educated
pharmacist in the future.
2. Materials and Methods
The mapping process was based on “intended curriculum” of the MDPharm program designed
and developed at the FP-UJCM. The MDPharm program documents consist of the courses syllabuses
and the program matrix table. The program matrix table shows which of the obligatory courses reflect
the sLO. The matrix table contains in the horizontal dimension the list of all obligatory courses and in
the vertical dimension the list of sLO. The matrix is completed separately every year, and is used in
quality control process to ensure that all sLO are presented in MDPharm program content.
The group of four academic teachers from FP-UJCM was involved in the mapping process. All of
them were pharmacists who were awarded their Diploma in Pharmacy at Jagiellonian University. Two
of the teachers were experienced academics (AS and AG) with at least ten years of experience in research
and teaching in pharmaceutical sciences, and two were less-experienced (JD and WP). All teachers
worked as community pharmacists in the past. Additionally, one of them (AS) was also employed in
the regional office of National Fund of Health, which was a legislative and financial institution.
The mapping process consisted of two steps. In the first step, each academic fulfilled the matrix
of competencies (in the vertical dimension) and sLO (in the horizontal dimension). So, the academics
had to decide whether the sLO reflects the specific competence (from the European Competence
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Framework). In the second step, the matrix of competencies and sLO were translated to courses
(from the MDPharm program). We use the program matrix table to attribute each competence to a
specific obligatory course. A schedule of the mapping process is presented in Figure 1.
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Finally, a quantitative analysis was done to identify gaps in the existing program. We summarize
the number of courses in which learning outcomes in knowledge and skills reflect the specific
competence. We also subjectively categorize the required level of the competence using the Dutch
Competenc Standard Framework, whic consists of five levels. The gradation of students’ knowledge,
skills, and professional behavior starts from level one, wher the student demonstrates knowledge
and basic professional beh vior and ends on level five, where student “independently performs the
professional activity” [14].
3. Results
3.1. Matrix of Learning Outcomes versus Competence
We assumed that a specific competence was reflected by a specific learning outcome if it was
marked by at least two of the academics. The qualitative analysis of the competence vs. learning
outcomes matrix showed the following:
– each competence was reflected by 23 sLO on average (the median value = 20), the maximum
number of sLO reflecting the separate competence was 72, and there were two competencies
which was not reflected by any of sLO; on average, competencies were reflected by 13 knowledge
sLO (the median value = 10) and 10 skills sLO (the median value = 9)
– each sLO reflected three co petencies on average (the median value = 2), most sLO reflected two
competencies (mode)
The detailed data of some knowledge and skills sLO covering the group of competencies is
presented in Table 3.
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Table 3. Qualitative and quantitative analysis of the distribution of the learning outcomes in the
European Competence Framework (ECF) [9,12].
Learning outcomes
Knowledge Skills
1. Personal competences:
learning and knowledge
1.1. Ability to identify learning needs and to learn independently
(including continuous professional development (CPD)). 1 1
1.2. Ability to apply logic to problem solving. 0 0
1.3. Ability to critically appraise relevant knowledge and to
summarise the key points. 1 1
1.4. Ability to evaluate scientific data in line with current scientific
and technological knowledge. 3 12
1.5. Ability to apply preclinical and clinical evidence-based medical
science to pharmaceutical practice. 10 14
1.6. Ability to apply current knowledge of relevant legislation and
codes of pharmacy practice. 15 9
2. Personal competences:
values
2.1. A professional approach to tasks and human relations. 3 2
2.2. Ability to maintain confidentiality. 4 2
2.3. Ability to take full responsibility for patient care. 7 1
2.4. Ability to inspire the confidence of others in one’s actions
and advice. 8 1
2.5. Knowledge of appropriate legislation and of ethics. 24 10
3. Personal competences:
communication and
organisational skills.
3.1. Ability to communicate effectively—both oral and written—in
the locally relevant language. 2 4
3.2. Ability to effectively use information technology. 3 7
3.3. Ability to work effectively as part of a team. 5 6
3.4. Ability to implement general legal requirements that impact
upon the practice of pharmacy (e.g., health and safety legislation,
employment law).
8 1
3.5. Ability to contribute to the training of staff. 4 1
3.6. Ability to manage risk and quality of service issues. 1 1
3.7. Ability to identify the need for new services. 0 0
3.8. Ability to understand a business environment and develop
entrepreneurship. 2 1
4. Personal competences:
research and industrial
pharmacy.
4.1. Knowledge of design, synthesis, isolation, characterisation and
biological evaluation of active substances. 56 15
4.2. Knowledge of good manufacturing practice and of good
laboratory practice. 29 34
4.3. Knowledge of European directives on qualified persons. 3 3
4.4. Knowledge of drug registration, licensing and marketing. 11 9
4.5. Knowledge of the importance of research in pharmaceutical
development and practice. 24 16
5. Patient care
competences—patient
consultation and
assessment.
5.1. Ability to interpret basic medical laboratory tests. 6 13
5.2. Ability to perform appropriate diagnostic tests e.g., measurement
of blood pressure or blood sugar. 4 7
5.3. Ability to recognise when referral to another member of the
healthcare team is needed. 8 0
6. Patient care
competences—need for
drug treatment.
6.1. Ability to retrieve and interpret information on the patient’s
clinical background. 25 2
6.2. Ability to compile and interpret a comprehensive drug history for
an individual patient. 5 2
6.3. Ability to identify non-adherence to medicine therapy and make
an appropriate intervention. 3 0
6.4. Ability to advise physicians on the appropriateness of prescribed
medicines and—in some cases—to prescribe medication. 17 23
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Learning outcomes
Knowledge Skills
7. Patient care
competences–drug
interactions.
7.1. Ability to identify and prioritise drug-drug interactions and
advise appropriate changes to medication. 23 14
7.2. Ability to identify and prioritise drug-patient interactions,
including those that prevent or require the use of a specific drug,
based on pharmaco-genetics, and advise on appropriate
changes to medication.
29 13
7.3. Ability to identify and prioritise drug-disease interactions
(e.g., NSAIDs in heart failure) and advise on appropriate
changes to medication.
11 14
8. Patient care
competences: drug dose
and formulation.
8.1. Knowledge of the bio-pharmaceutical, pharmacodynamic and
pharmacokinetic activity of a substance in the body. 42 30
8.2. Ability to recommend interchangeability of drugs based on
in-depth understanding and knowledge of bioequivalence,
bio-similarity and therapeutic equivalence of drugs.
24 21
8.3. Ability to undertake a critical evaluation of a prescription
ensuring that it is clinically appropriate and legally valid. 15 5
8.4. Knowledge of the supply chain of medicines thus ensuring timely
flow of quality drug products to the patient. 3 0
8.5. Ability to manufacture medicinal products that are not
commercially available. 17 7
9. Patient care
competences–patient
education.
9.1. Ability to promote public health in collaboration with other
professionals within the healthcare system. 9 9
9.2. Ability to provide appropriate lifestyle advice to improve patient
outcomes (e.g., advice on smoking, obesity, etc.). 24 12
9.3. Ability to use pharmaceutical knowledge and provide
evidence-based advice on public health issues involving medicines. 30 8
10. Patient care
competences–provision
of information and
service.
10.1. Ability to use effective consultations to identify the patient’s
need for information. 18 9
10.2. Ability to provide accurate and appropriate information on
prescription medicines. 22 34
10.3. Ability to provide evidence-based support for patients in
selection and use of non-prescription medicines. 24 30
11. Patient care
competences–monitoring
of drug therapy.
11.1. Ability to identify and prioritise problems in the management of
medicines in a timely and effective manner and so ensure patient
safety.
12 22
11.2. Ability to monitor and report Adverse Drug Events and
Adverse Drug Reactions (ADEs and ADRs) to all concerned, in a
timely manner, and in accordance with current regulatory guidelines
on Good Pharmacovigilance Practices (GVPs).
21 17
11.3. Ability to undertake a critical evaluation of prescribed medicines
to confirm that current clinical guidelines are appropriately applied. 19 14
11.4. Ability to monitor patient care outcomes to optimise treatment
in collaboration with the prescriber. 18 20
11.5. Ability to contribute to the cost effectiveness of treatment by
collection and analysis of data on medicines use. 10 19
3.2. Matrix of Competencies versus Courses
The courses were grouped according to the scientific fields (as described in Table 3) and to the
year of the study; we also included the scientific project, holiday, and final internships.
Most of the Personal competencies in learning and knowledge are covered by the courses in group C,
which are offered mostly at final years of the study. The Personal competencies: Values are covered by
the first and senior years of study, which offer ethics courses on the one hand, and on the other the
senior internship, where the student has an opportunity to observe “real life” and to develop their
attitude toward the ethical dilemma. The Personal competencies such as communication and organization
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skills and research and industrial pharmacy seem to be balanced between all groups of courses and all
study years. The details of the distribution of personal competencies between topic groups and the years
of the MDPharm are shown in Table 4.
The Patient Care Competencies are less covered by courses from the group B (physics and chemistry),
which are mainly offered to the second year students. FP-UJCM students may achieve most of the
Patient Care Competencies at the senior years of their MDPharm (fourth to sixth years). The details of the
distribution of Patient Care Competencies between topic groups and years of the MDPharm are shown
in Table 5.
Table 4. Quantitative analysis of the distribution of the Personal competencies into the group of courses
or the study year at FP-UJ CM [12].
PERSONAL COMPETENCE
G
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U
P
A
(n
=
13
)
G
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U
P
B
(n
=
8)
G
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A
(n
=
13
)
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(N
=
6)
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N
=
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1(
N
=
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)
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R
2(
N
=
6)
Y
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R
3(
N
=
8)
Y
EA
R
4(
N
=
10
)
Y
EA
R
5+
6(
N
=
9)
n n n n n n n n n n
LEARNING AND
KNOWLEDGE
1.1. Ability to identify learning needs and to learn
independently (including continuous professional
development (CPD)).
1 1
1.2. Ability to apply logic to problem solving.
1.3. Ability to critically appraise relevant knowledge and to
summarise the key points. 1 1 1
1.4. Ability to evaluate scientific data in line with current
scientific and technological knowledge. 4 1 4 4 1 2 2
1.5. Ability to apply preclinical and clinical evidence-based
medical science to pharmaceutical practice. 1 3 5 1 4 4
1.6. Ability to apply current knowledge of relevant legislation
and codes of pharmacy practice. 1 7 1 2 5
VALUES
2.1. A professional approach to tasks and human relations. 3 4 1 1 1 4
2.2. Ability to maintain confidentiality. 2 1 2 1 1 1 2
2.3. Ability to take full responsibility for patient care. 1 3 1 3
2.4. Ability to inspire the confidence of others in one’s actions
and advice. 2 5 1 1 5
2.5. Knowledge of appropriate legislation and of ethics. 1 1 6 1 2 5
COMMUNICATION
AND
ORGANISATIONAL
SKILLS
3.1. Ability to communicate effectively–both oral and
written–in the locally relevant language. 1 2 1 2 2 2 2 2 2
3.2. Ability to effectively use information technology. 4 2 3 1 2
3.3. Ability to work effectively as part of a team. 1 3 1 3 2 1 1 2 2
3.4. Ability to implement general legal requirements that
impact upon the practice of pharmacy (e.g., health and safety
legislation, employment law).
4 4
3.5. Ability to contribute to the training of staff. 3 1 1 1
3.6. Ability to manage risk and quality of service issues. 1 2 1 1 1
3.7. Ability to identify the need for new services.
3.8. Ability to understand a business environment and
develop entrepreneurship. 1 1
RESEARCH AND
INDUSTRIAL
PHARMACY
4.1. Knowledge of design, synthesis, isolation,
characterisation and biological evaluation of active
substances.
2 7 5 4 5 4 2 3 3
4.2. Knowledge of good manufacturing practice and of good
laboratory practice. 8 3 7 4 5 4 5 4 3
4.3. Knowledge of European directives on qualified persons. 4 2 2 1 2
4.4. Knowledge of drug registration, licensing and marketing. 6 1 7 2 3 8
4.5. Knowledge of the importance of research in
pharmaceutical development and practice. 1 4 7 2 1 4 1 2 4 3
N–total number of courses in the group or study year, n–number of courses reflecting the specific competence.
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Table 5. Quantitative analysis of the distribution of the Patient care competencies into the topic groups or
the year of the pharmacy course at FP-UJ CM [12].
PATIENT CARE COMPETENCE
G
R
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U
P
A
(n
=
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)
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R
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U
P
B
(n
=
8)
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U
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A
(n
=
13
)
G
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D
(N
=
6)
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E(
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=
10
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R
3(
N
=
8)
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EA
R
4(
N
=
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)
Y
EA
R
5+
6(
N
=
9)
n n n n n n n n n n
PATIENT
CONSULTATION
AND ASSESSMENT
5.1. Ability to interpret basic medical laboratory tests. 5 1 1 1 2 2 3 1
5.2. Ability to perform appropriate diagnostic tests e.g., measurement
of blood pressure or blood sugar. 4 1 1 2 2 2
5.3. Ability to recognize when referral to another member of the
healthcare team is needed. 1 2 4 1 2 4
NEED FOR DRUG
TREATMENT
6.1. Ability to retrieve and interpret information on the patient’s
clinical background. 9 2 2 3 3 3 1 2
6.2. Ability to compile and interpret a comprehensive drug history for
an individual patient. 1 1 1 2 1 2 2
6.3. Ability to identify non-adherence to medicine therapy and make
an appropriate intervention. 2 2
6.4. Ability to advise physicians on the appropriateness of prescribed
medicines and–in some cases–to prescribe medication. 1 1 5 5 6 1 3 5 8
DRUG
INTERACTIONS
7.1. Ability to identify and prioritise drug-drug interactions and advise
appropriate changes to medication. 7 1 5 2 3 2 4 3 3
7.2. Ability to identify and prioritise drug-patient interactions,
including those that prevent or require the use of a specific drug,
based on pharmaco-genetics, and advise on appropriate
changes to medication.
6 3 5 2 2 2 4 3 4
7.3. Ability to identify and prioritise drug-disease interactions
(e.g., NSAIDs in heart failure) and advise on appropriate
changes to medication.
3 5 2 2 3 4
DRUG DOSE AND
FORMULATION
8.1. Knowledge of the bio-pharmaceutical, pharmacodynamic and
pharmacokinetic activity of a substance in the body. 9 1 6 5 2 4 3 6 5 4
8.2. Ability to recommend interchangeability of drugs based on
in-depth understanding and knowledge of bioequivalence,
bio-similarity and therapeutic equivalence of drugs.
6 6 3 5 3
8.3. Ability to undertake a critical evaluation of a prescription ensuring
that it is clinically appropriate and legally valid. 5 4 2 3 3 4
8.4. Knowledge of the supply chain of medicines thus ensuring timely
flow of quality drug products to the patient. 2 2
8.5. Ability to manufacture medicinal products that are not
commercially available. 1 5 3 1 1 3 2 3
PATIENT
EDUCATION
9.1. Ability to promote public health in collaboration with other
professionals within the healthcare system. 4 2 2 1 3 1 3
9.2. Ability to provide appropriate lifestyle advice to improve patient
outcomes (e.g., advice on smoking, obesity, etc.). 9 2 1 3 3 3 2 1
9.3. Ability to use pharmaceutical knowledge and provide
evidence-based advice on public health issues involving medicines. 6 3 4 2 2 2 4 3
PROVISION OF
INFORMATION AND
SERVICE
10.1. Ability to use effective consultations to identify the patient’s need
for information. 5 2 5 3 2 3 4
10.2. Ability to provide accurate and appropriate information on
prescription medicines. 2 5 5 5 1 3 5 7
10.3. Ability to provide evidence-based support for patients in
selection and use of non-prescription medicines. 2 5 5 5 1 3 4 8
MONITORING OF
DRUG THERAPY
11.1. Ability to identify and prioritise problems in the management of
medicines in a timely and effective manner and so ensure patient
safety.
1 3 4 4 1 2 3 6
11.2. Ability to monitor and report Adverse Drug Events and Adverse
Drug Reactions (ADEs and ADRs) to all concerned, in a timely manner,
and in accordance with current regulatory guidelines on Good
Pharmacovigilance Practices (GVPs).
4 4 4 1 6 5
11.3. Ability to undertake a critical evaluation of prescribed medicines
to confirm that current clinical guidelines are appropriately applied. 2 5 6 7 2 3 7 8
11.4. Ability to monitor patient care outcomes to optimize treatment in
collaboration with the prescriber. 1 1 5 5 6 2 2 6 8
11.5. Ability to contribute to the cost effectiveness of treatment by
collection and analysis of data on medicines use. 4 4 2 4 3 1 2 4 4
N–total number of courses in the group or study year, n–number of courses reflecting the specific competence.
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3.3. Analysis of the Level of Competencies
We based our subjective analysis (which reflects the levels of the Dutch Competence Standard
Framework) on the document on the one hand, and our personal experience as a pharmacist and a
teacher on the other. Two of our colleagues (JD and WP) could also use their experience as a pharmacy
student because at least half of their courses were established basing on Bologna process. We also took
into account the composition of knowledge sLO and skills sLO covering the specific competence as
well as a teaching and assessing methods described in the course syllabus. The results of our discussion
are presented in Table 6. In the brackets, we listed the numbers of the competencies (according to the
Tables 4 and 5) which could be achieved on the specific level at the end of the MDPharm program.
Table 6. A desk analysis of the level of competence achieved by a student at the MDPharm program at
FP-UJCM [14].
Level *
Personal Competencies
learning and knowledge 1a (1,3,4); 1c (5,6)
values 2 (3,4); 3 (5); 4 (1,2)
communication and organisational skills 1a (1,3); 1c (4); 2 (6); 3 (7,8); 4 (2)
research and industrial pharmacy 1c (3,5); 3 (2,4); 5 (1)
Patient Care Competencies
patient consultation and assessment 1a (1,3)
need for drug treatment 1a (2,3); 1c (1,4)
drug interactions 1a (1); 2 (2,3)
drug dose and formulation 1c (2); 2 (5); 3 (1,4); 4 (3)
patient education 1c (2); 2 (3); 3 (1)
provision of information and service 1c (1); 2 (2,3)
monitoring of drug therapy 1a (3,5); 2 (1); 4 (2,4)
* the level of Dutch Competence Standard Framework; in the brackets, we used the numbers of the specific
competencies from Tables 4 and 5.
Most of the competencies (n = 12) seem to be possible to be achieved by students on the level 1
(1a to 1 c), which is a basic level and means that a student can present the knowledge and demonstrate
professional behavior only in a test situation.
4. Discussion
The mapping process of the curriculum at the FP-UJCM was a part of the cooperation of the
partners of the PHAR-QA Consortium [12], and by the discussion between partners, it was limited
to “intended curriculum” mapping. We mapped the “intended curriculum” based only on official
documents of the MDPharm program at our faculty, which means that the results of our analysis did
not reflect the opinion of the students or another teacher. We hope it can be used to identify the gaps
and to see what could be improved in future [15].
The MDPharm program at Jagiellonian University is based on learning outcomes defined at the
national level [9]. It educates students to be future professional staff in a community and hospital
pharmacy, so the patient-oriented European Competence Framework [13] should be widely represented
and recognized in the curriculum documents.
In the first step of our analysis, we had to “translate” the sLO created for knowledge, professional,
and social skills into the competencies. We observed a high inconsistency among the total number of
sLO, which could be recognized as reflecting the specific Personal competencies. For example, we found:
– 71 sLO (56 in knowledge and 15 in skills) which we matched to competence: Knowledge of design,
synthesis, isolation, characterization and biological evaluation of active substances (4.1 in Table 3)
– only two sLO (one in knowledge and one in skills) for competencies:
# ability to identify learning needs and to learn independently (including continuous professional
development (CPD)-1.1 in Table 3);
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# ability to critically appraise relevant knowledge and to summarize the key points (1.3 in Table 3);
# ability to manage risk and quality of service issues (see 3.6 in Table 3).
– two Personal competence: ability to apply logic to problem-solving (1.2 in Table 3) and ability to identify
the need for new services (3.7 in Table 3), which we could not recognize as directly represented by
sLO, and consequently, delivered by any obligatory course.
A similar situation was recognized in the group of Patient care competencies, where:
– 72 sLO (42 in knowledge and 30 in skills) reflected the competence Knowledge of the
bio-pharmaceutical, pharmacodynamic and pharmacokinetic activity of a substance in the body (8.1 in
Table 3)
– only three sLO (in knowledge) reflected the competence Ability to identify non-adherence to medicine
therapy and make an appropriate intervention (6.3 in Table 3) and Knowledge of the supply chain of
medicines thus ensuring timely flow of quality drug products to the patient (8.4 in Table 3).
The analysis of the distribution of competences among the study years (Tables 4 and 5) showed
that a student has an opportunity to achieve personal competencies mostly during the senior years of the
study (5th and 6th year). Only competencies in research and industrial pharmacy are distributed equally
at the junior and senior years of the study. Students achieve the patient care competencies at the 3rd, 4th,
5th, and 6th years of the study. However, most of them—especially in the group provision of information
and services—are distributed among the courses of the last three years (4th to 6th).
Based on the Dutch Competence Standard Framework [14], we also tried to subjectively assess
the level of competencies achieved by the student [14]. In general, we assumed (Table 6) that most
competencies are achieved at a level 1 or 2. There is a limited group of competencies among Personal
competencies and patient care competencies which could be considered as achieved at the 4th level,
and only one—knowledge of design, synthesis, isolation, characterization and biological evaluation of active
substances—which could be achieved at a level 5. We can conclude that despite wide reflection of the
need for drug treatment or provision of information and service competencies in the sLO, the subjective
assessment showed that it is highly possible that a student can only present the knowledge about the
specific competence and demonstrate the skills only in a test situation. This means that she is not
“able to adequately carry out professional activities in an authentic professional situation under the
supervision of an experienced practitioner” [14].
A major limitation of the mapping process based on “intended curriculum” is the fact that it
is based on documents only, so we could not be sure that the ideas described in documents are
implemented into the daily teaching activity. This means that even those competencies which we
recognized as “well” reflected by the sLO might not be achieved by all students. To verify the results
of our study, we plan to extend the analysis, and we are planning the study of the student's perception
about their competencies.
Because the results of our analysis already showed gaps and lack of balance between competencies
and learning outcomes, we will recommend Dean’s office to start the discussion with the teachers at
FP-UJ CM to encourage them to switch to competence-based learning.
The main conclusion of our analysis is that the education system for pharmacy in Poland based
on learning outcomes does not directly reflect the competencies. This means that to start with
competence-based pharmacy education, we need to change the legal regulation at the national level
and redefine our teaching at the university level. Despite the changes in the national regulations in the
pharmacy field, academics should remember that their main obligation is to ensure that their graduates
will be able to work independently and responsibly to improve the health of the society and to ensure
the safe and effective use of drugs. As academics who are experienced in teaching, we have to be
aware of our responsibility for creating the professional attitude and competencies of our students.
As pharmacists and academics, we are also responsible for developing the professional education
system to let our students become the professionals of the future.
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